Skip to content
10-K

Annual Report

ELITE PHARMACEUTICALS INC /NV/ ELTP

0001641172-25-017134

← back to feed
Filed
Jun 30, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Jun 27, 2025 1.07B sh
Shares Diluted FY 2025 · Mar 31, 2025 1.07B sh
Shares Diluted FY 2025 · Mar 31, 2024 1.02B sh
Capex FY 2025 · Mar 31, 2025 $1.63M
Capex FY 2025 · Mar 31, 2024 $809.65K
Operating Cash Flow FY 2025 · Mar 31, 2025 $7.46M
Operating Cash Flow restated FY 2025 · Mar 31, 2024 −$3.24M
Stockholders Equity FY 2025 · Mar 31, 2025 $53.52M
Stockholders Equity FY 2025 · Mar 31, 2024 $57.58M
Stockholders Equity FY 2025 · Mar 31, 2023 $28.96M
Current Liabilities FY 2025 · Mar 31, 2025 $11.84M
Current Liabilities FY 2025 · Mar 31, 2024 $13.05M
Total Liabilities FY 2025 · Mar 31, 2025 $42.87M
Total Liabilities FY 2025 · Mar 31, 2024 $26.07M
Current Assets FY 2025 · Mar 31, 2025 $57.74M
Current Assets FY 2025 · Mar 31, 2024 $40.01M
Total Assets FY 2025 · Mar 31, 2025 $96.39M
Total Assets FY 2025 · Mar 31, 2024 $83.65M
Eps Diluted FY 2025 · Mar 31, 2025 $0.00
Eps Diluted FY 2025 · Mar 31, 2024 $0.02
Eps Basic FY 2025 · Mar 31, 2025 $0.00
Eps Basic FY 2025 · Mar 31, 2024 $0.02
Sga Expense FY 2025 · Mar 31, 2025 $9M
Sga Expense FY 2025 · Mar 31, 2024 $7.15M
Rd Expense FY 2025 · Mar 31, 2025 $7.96M
Rd Expense FY 2025 · Mar 31, 2024 $6.88M
Net Income FY 2025 · Mar 31, 2025 −$4.31M
Net Income FY 2025 · Mar 31, 2024 $20.11M
Operating Income FY 2025 · Mar 31, 2025 $19.6M
Operating Income FY 2025 · Mar 31, 2024 $10.79M
Gross Profit FY 2025 · Mar 31, 2025 $40.09M
Gross Profit FY 2025 · Mar 31, 2024 $26.36M
Cost Of Revenue FY 2025 · Mar 31, 2025 $43.96M
Cost Of Revenue FY 2025 · Mar 31, 2024 $30.27M
Revenue FY 2025 · Mar 31, 2025 $84.04M
Revenue FY 2025 · Mar 31, 2024 $56.63M